Zamora, I.; Freeman, M.R.; Encío, I.J.; Rotinen, M. Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer. Int. J. Mol. Sci.2023, 24, 13673.
Zamora, I.; Freeman, M.R.; Encío, I.J.; Rotinen, M. Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer. Int. J. Mol. Sci. 2023, 24, 13673.
Zamora, I.; Freeman, M.R.; Encío, I.J.; Rotinen, M. Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer. Int. J. Mol. Sci.2023, 24, 13673.
Zamora, I.; Freeman, M.R.; Encío, I.J.; Rotinen, M. Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer. Int. J. Mol. Sci. 2023, 24, 13673.
Abstract
Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer (PC) that commonly emerges through a transdifferentiation process from prostate adenocarcinoma and evades conventional therapies. Extensive molecular research has revealed factors that drive lineage plasticity, uncovering novel therapeutic targets to be explored. A diverse array of targeting agents is currently under evaluation in pre-clinical and clinical studies with promising results in suppressing or reversing the neuroendocrine phenotype and inhibiting tumor growth and metastasis. This new knowledge has the potential to contribute to development of novel therapeutic approaches that may enhance clinical management and prognosis of this lethal disease.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
